Stockscreener 앱 받기
4.095
10.00%
-0.455
시간 외 거래:
4.13
0.035
+0.85%
Recursion Pharmaceuticals Inc 주식(RXRX)의 최신 뉴스
(RXRX) Technical Data - news.stocktradersdaily.com
Transcript : Recursion Pharmaceuticals, Inc. Presents at 53rd Annual JPMorgan Global Technology, Media and Communications Conference, May-15-2025 10 - marketscreener.com
Recursion Pharmaceuticals, Inc. (RXRX) Nosedives 36.55% As AI Drug Discovery Dreams Stall - Insider Monkey
Recursion Pharmaceuticals Plunges 22% in May: How to Play the Stock - Zacks Investment Research
10 Most Popular AI Stocks to Avoid Now - Insider Monkey
Recursion Pharmaceuticals: High-Risk Play Getting Riskier By The Quarter (NASDAQ:RXRX) - Seeking Alpha
Recursion Pharmaceuticals, Inc. (RXRX): Among the Best Artificial Intelligence Stocks Under $50 to Buy Now - MSN
13 Best Artificial Intelligence Stocks Under $50 to Buy Now - Insider Monkey
Transcript : Recursion Pharmaceuticals, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-13-2025 10 - marketscreener.com
Should You Buy This Beaten-Down Artificial Intelligence (AI) Stock on the Dip? - The Globe and Mail
How Recursion Is Industrializing Clinical Trials With AI - Clinical Leader
Recursion Pharmaceuticals outlines focused R&D pipeline with multiple catalysts through 2026 - MSN
Recursion Pharmaceuticals files prospectus supplement By Investing.com - Investing.com India
Recursion Pharmaceuticals files prospectus supplement - Investing.com Australia
Why Recursion Pharmaceuticals Stock Plummeted 24% This Week - Mitrade
Recursion Pharmaceuticals Registers Shares for Resale - TipRanks
(RXRX) Long Term Investment Analysis - news.stocktradersdaily.com
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q1 2025 Earnings Call Transcript - MSN
Retail Traders Bearish On Recursion Pharma Ahead of Q1 Results Despite Positive Tupelo Trial Data - MSN
RXRX Stock Down 17% as Q1 Earnings & Revenues Miss Estimates - MSN
Earnings Release: Here's Why Analysts Cut Their Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target To US$7.43 - Yahoo Finance
Why Recursion Pharmaceuticals Stock Is Plummeting Today - The Globe and Mail
Recursion axes drug programmes to streamline pipeline - Yahoo Finance
Recursion to Participate in Upcoming Investor Conferences - The Manila Times
BofA Adjusts Price Target for RXRX Following Pipeline Changes | RXRX Stock News - GuruFocus
Recursion Pharmaceuticals Inc (RXRX) Q1 2025 Earnings Call Highlights: Strategic Partnerships ... By GuruFocus - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Str - GuruFocus
Recursion Pharmaceuticals Reports Q1 2025 Financial Results - TipRanks
Recursion Pharmaceuticals: Q1 Earnings Snapshot - MySA
Recursion Pharmaceuticals’ Earnings Call: Balancing Success and Challenges - TipRanks
Recursion Pharmaceuticals Q1 2025 Earnings: EPS Beats Estimates at -$0.50, Revenue Misses at $15 Million - GuruFocus
Recursion Pharmaceuticals (RXRX) Reports Q1 Earnings: EPS Surpas - GuruFocus
Recursion (RXRX) Reports Q1 Revenue Shortfall, Focuses on Stream - GuruFocus
Why Recursion Pharmaceuticals Stock Was Getting Mashed on Monday - Mitrade
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates By Investing.com - Investing.com South Africa
Earnings call transcript: Recursion Pharmaceuticals Q1 2025 results miss estimates - Investing.com Nigeria
Recursion Pharmaceuticals (RXRX) Advances Drug Programs with Strategic Focus - GuruFocus
Recursion Pharmaceuticals (NasdaqGS:RXRX) Reports Q1 Sales Increase and REC-4881 Trial Results - Yahoo Finance
Recursion Pharmaceuticals Q1 2025 Earnings Call Transcript - MarketBeat
AI specialist Recursion trims pipeline in latest shakeup - BioPharma Dive
Why Recursion Pharmaceuticals Stock Was Getting Mashed On Monday - Barchart.com
Recursion Deprioritizes 3 Clinical Programs Following Data-Driven Review, Stock Down - Nasdaq
Document - SEC.gov
Recursion Pharmaceuticals earnings missed by $0.01, revenue fell short of estimates - Investing.com Canada
Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Recursion Pharmaceuticals Q1 Loss Widens, Revenue Increases - marketscreener.com
1.52%
1.15%
자본화:
|
볼륨(24시간):